Tracking Outcomes in Pain Patients Using Fitness Devices
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
Studietype
Studietype
Registrering (Faktiske)
Registrering
Kontakter og plasseringer
Studiesteder
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 275997010
- UNC Chapel Hill
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Back pain which may benefit from epidural injection
- Assenting to epidural injection for back pain
Exclusion Criteria:
- Inability to wear fitness tracking device
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Antall grupper / kohorter
Kohorter og intervensjoner
Gruppe / KohortGruppe / Kohort |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Back pain receiving epidural injection
Patients who have chronic back pain and are scheduled for an epidural injection to treat this pain will be receive a transforaminal epidural steroid injection as determined by routine care provider
|
After evaluation by their pain physician, if the clinician offers an epidural injection for their back pain, they will be followed for this study before and after the injection.
Betamethasone Triamcinolone Dexamethasone Methylprednisolone Lidocaine Bupivacaine Ropivacaine Normal saline
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Association of percent improvement in pain and number of steps.
Tidsramme: Follow-up assessment approximately 2-4 weeks following epidural procedure.
|
Linear regression will be used to determine the association of change in percent improvement of pain (assessed at baseline and follow-up) and number of steps taken on average the week of the assessment.
Increased beta-coefficient from linear regression demonstrates that increased improvement in pain is related to an increased number of steps indicating improved mobility.
If the beta coefficient from the linear regression is negative, this indicates that percent improvement in pain is associated with decreased number of steps and reduced mobility.
|
Follow-up assessment approximately 2-4 weeks following epidural procedure.
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in pain severity following procedure
Tidsramme: Follow-up timepoint approximately 2-4 weeks following procedure
|
Pain will be assessed by using a Visual Analog Scale (VAS) where scores range from 0 = no pain to 100 = worst possible pain.
An increase in pain scores from baseline represent disease progression and decrease represent clinical response to treatment.
VAS will be assessed prior to treatment and then at a followup assessment.
|
Follow-up timepoint approximately 2-4 weeks following procedure
|
|
Association in minutes slept as measured by fitness device and percent improvement in pain
Tidsramme: Follow-up assessment approximately 2-4 week following procedure
|
Linear regression will be used to determine the association of change in percent improvement of pain (assessed at baseline and follow-up) and number of minutes slept on average the week of the assessment.
Increased beta-coefficient from linear regression demonstrates that increased improvement in pain is related to an increased number of steps indicating improved mobility.
If the beta coefficient from the linear regression is negative, this indicates that percent improvement in pain is associated with decreased number of steps and reduced mobility.
|
Follow-up assessment approximately 2-4 week following procedure
|
|
Change in survey measures of pain
Tidsramme: Follow-up assessment approximately 2-4 weeks following the procedure.
|
Conglomerate survey device of brief pain inventory, roland morris disability questionnaire, and oswestry disability index.
The investigators will measure baseline survey data before the treatment and then at follow up visit.
|
Follow-up assessment approximately 2-4 weeks following the procedure.
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Samarbeidspartnere
Samarbeidspartnere
Etterforskere
Etterforskere
- Hovedetterforsker: Matthew C Mauck, MD PhD, Assistant Professor
Studierekorddatoer
Studer hoveddatoer
Studiestart
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Faktiske)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- 14-2949
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .